Fusion Pharmaceuticals
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha therapeutics (actinium-225 radiopharmaceuticals with proprietary Fast-Clear™ linkers) for cancers including prostate, lung, and gastrointestinal tumors, now a wholly-owned AstraZeneca subsidiary.
- Company typePrivate
- Founded2015
- HeadquartersHamilton, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fusion Pharmaceuticals does
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted alpha therapeutics (TAT) for the treatment of cancer, built around actinium-225 alpha-emitting isotopes combined with proprietary Fast-Clear™ linker technology. The platform pairs medical isotopes with cancer-targeting molecules (antibodies, small molecules, centyrins) to deliver lethal double-stranded DNA breaks selectively to tumor cells while sparing healthy tissue, with three distinct mechanisms of action: direct DNA damage, bystander effect, and alpha-particle-mediated immune activation.
The company's pipeline includes FPI-2265 (lead asset, 225Ac-PSMA I&T in Phase 2 TATCIST for metastatic castration-resistant prostate cancer, including both PSMA-naïve and 177Lu-PSMA-pretreated patients), FPI-1434 (Phase 1 anti-IGF-1R radioimmunoconjugate for solid tumors with imaging analogue FPI-1547), FPI-2059 (anti-NTSR1 acquired from Ipsen for pancreatic, colorectal, and gastric cancers), and FPI-2068 (anti-EGFR/cMET co-developed with AstraZeneca, FDA IND clearance April 2023). Preclinical assets include FPI-1966 (FGFR3 for bladder cancer) and FPI-1848 (TEM-1 for sarcoma).
Fusion was founded in 2015 as a spin-out from McMaster University's Centre for Probe Development and Commercialization (CPDC), headquartered in Hamilton, Ontario, with US operations in Boston, MA. The company raised approximately $231M in equity across Series A, Series B, a CPPIB commitment, and a 2023 private placement before being acquired by AstraZeneca in June 2024 for approximately $2.4 billion. Pre-acquisition business model was research-driven with no commercial revenue; future monetization was expected through direct commercialization (specialty/hospital pharmacy distribution for short-half-life alpha radiopharmaceuticals) and strategic partnerships.
Fusion Pharmaceuticals firmographics
Firmographics- Name
- Fusion Pharmaceuticals
- Legal name
- Fusion Pharmaceuticals Inc.
- Website
- https://fusionpharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha therapeutics (actinium-225 radiopharmaceuticals with proprietary Fast-Clear™ linkers) for cancers including prostate, lung, and gastrointestinal tumors, now a wholly-owned AstraZeneca subsidiary.
- Ownership category
- akta.pro rank
Fusion Pharmaceuticals industry classification
Industry- Product category
- Targeted Alpha Therapeutics / Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)
Keywords
Where Fusion Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Hamilton
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Fusion Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Radiopharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage company developing targeted alpha therapeutics pipeline. Revenue expected from future drug commercialization upon regulatory approval. Multiple candidates in clinical development targeting prostate cancer and solid tumors.
Go-to-market motion1 record
Marketing channels3 records
Fusion Pharmaceuticals product offering
Product offeringCore offering
Fusion Pharmaceuticals develops clinical-stage targeted alpha therapeutics (TAT) that use actinium-225 alpha-emitting isotopes conjugated to tumor-targeting molecules (antibodies, small molecules) via its proprietary Fast-Clear™ linker technology. Lead asset FPI-2265 is in Phase 2 for metastatic castration-resistant prostate cancer, with additional candidates targeting IGF-1R, NTSR1, EGFR/cMET, FGFR3, and TEM-1 expressing tumors.
Product overview
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for cancer treatment. The company's portfolio consists of multiple targeted alpha therapeutics (TAT) using actinium-225, built on its proprietary Fast-Clear linker technology platform. Key products include FPI-2265 (lead program, Phase 2 for mCRPC), FPI-1434 (Phase 1 for IGF-1R expressing solid tumors), FPI-2059 (NTSR1-targeted for solid tumors), FPI-2068 (EGFR/cMET-targeting), and several preclinical candidates (FPI-1966, FPI-1848). The Fast-Clear linker technology differentiates the platform by promoting rapid excretion of unbound isotopes to improve safety and expand the therapeutic window.
Differentiator
Problem solved
Functional benefit
Products and services
- FPI-2265 (225Ac-PSMA I&T) Alpha-emitting radiopharmaceutical using actinium-225 conjugated to a PSMA-targeting small molecule, in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). Built on Fusion's Fast-Clear linker technology.
- FPI-1434 Targeted alpha radioimmunoconjugate consisting of anti-IGF-1R humanized monoclonal antibody, Fusion's Fast-Clear linker, a bifunctional chelate, and actinium-225. In Phase 1 for solid tumors expressing IGF-1R (non-small cell lung, prostate, sarcomas, breast).
- FPI-2059 Small-molecule targeted alpha therapy combining Ipsen's IPN-1087 NTSR1 ligand with actinium-225 for solid tumors overexpressing neurotensin receptor 1 (NTSR1), including pancreatic ductal adenocarcinoma, colorectal cancer, and gastric cancers.
- FPI-2068 Anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate co-developed with AstraZeneca for cancer therapy; FDA IND cleared April 2023.
- FPI-1966 FGFR3-targeted alpha therapeutic using actinium-225; preclinical-stage asset for bladder cancer.
- FPI-1848 TEM-1-targeted alpha therapeutic using actinium-225; preclinical-stage asset for sarcoma.
- FPI-1547 Imaging/diagnostic analogue of FPI-1434 using indium-111 (111In) in place of actinium-225, used for patient selection and quantification of IGF-1R-expressing tumors prior to therapy.
Quantifiable outcome
- Phase 2 TATCIST trial evaluating FPI-2265 (225Ac-PSMA I&T) in mCRPC with initial data expected in early 2024
- +1 more outcomes
Companies that use Fusion Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles2 records
Fusion Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Fusion Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- AstraZenecaflagshipJoint development of FPI-2068, a novel anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate for cancer therapy. AstraZeneca subsequently acquired Fusion Pharmaceuticals for approximately $2.4 billion in 2024.
- RadioMedixcoreAcquisition of Investigational New Drug (IND) application for Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a targeted alpha therapy for metastatic castration-resistant prostate cancer.
- IpsencoreAcquisition of IPN-1087, a small molecule targeting neurotensin receptor 1 (NTSR1), in 2021. Previously in Phase 1 as lutetium-177 radiopharmaceutical; now being developed as actinium-225 targeted alpha therapeutic FPI-2059.
- ImmunoGencoreExclusive license to AVE1642 humanized antibody against IGF-1R for development as targeted alpha therapeutic FPI-1434. Previously in Phase I/II clinical trials.
- IsogenicacoreLicensing agreement to utilize Isogenica's proprietary in vitro CIS Display technology for discovery, development and commercialisation of therapeutic products derived from polypeptide libraries for targeted alpha therapeutics.
- Janssen BiotechcoreTwo licensing agreements for centyrin-based targeting molecules in combination with Fusion's labeling technologies. Centyrins are small proteins with high selectivity and specificity for cancer cell targeting.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Fusion Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Novartis: Novartis commercializes PLUVICTO (177Lu-PSMA-617), the leading approved PSMA-targeted radioligand therapy for mCRPC, and is the principal direct competitor to Fusion's lead FPI-2265 alpha-emitting program.
- Eli Lilly: Lilly acquired Point Biopharma and is investing heavily in radioligand therapy capabilities (including the BroadGBM and other partnerships), making it a strategic incumbent competitor for radiopharmaceutical talent, pipeline assets, and indications Fusion targets.
- Bayer: Bayer markets Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, providing direct therapeutic overlap and prior validation of alpha-emitter commercial viability.
- RayzeBio (Bristol Myers Squibb): RayzeBio, acquired by BMS, developed actinium-225-based radiopharmaceuticals for solid tumors, making it the most direct platform peer in targeted alpha therapy now backed by a global biopharma.
Emerging players
- Aktis Oncology: Aktis Oncology is an emerging clinical-stage developer of alpha-emitting radiopharmaceuticals for solid tumors, sharing Fusion's TAT platform approach using Ac-225 and proprietary targeting chemistry.
- Convergent Therapeutics: Convergent is a clinical-stage company developing alpha-emitting radioligand therapies (notably Ac-225 based) for prostate cancer, representing an emerging direct competitor in the same modality and indication.
Direct peers
- Telix Pharmaceuticals: Telix develops and commercializes PSMA-targeted imaging (Illuccix) and is advancing alpha-emitting radioligand therapies, closely mirroring Fusion's theranostic and TAT positioning.
- Lantheus Holdings: Lantheus markets PYLARIFY (Piflufolastat F-18) PSMA diagnostic imaging agent and acquired Point Biopharma to enter PSMA radioligand therapy, making it the closest comparable radiopharmaceutical platform with paired diagnostics and therapy.
- ITM Radiopharma: ITM is a clinical-to-commercial radiopharmaceutical platform developing both diagnostic and therapeutic radioligands across multiple targets, directly comparable to Fusion's Targeted Alpha Therapeutics platform.
- Point Biopharma: Point Biopharma (acquired by Lantheus) developed PSMA-targeted radioligand therapies (PNT2002) competing in the same mCRPC indication as Fusion's FPI-2265 with similar targeting approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Fusion Pharmaceuticals social profiles
Digital presenceFusion Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fusion Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Fusion Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fusion Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fusion Pharmaceuticals
What does Fusion Pharmaceuticals do?
Fusion Pharmaceuticals develops clinical-stage targeted alpha therapeutics (TAT) that use actinium-225 alpha-emitting isotopes conjugated to tumor-targeting molecules (antibodies, small molecules) via its proprietary Fast-Clear™ linker technology. Lead asset FPI-2265 is in Phase 2 for metastatic castration-resistant prostate cancer, with additional candidates targeting IGF-1R, NTSR1, EGFR/cMET, FGFR3, and TEM-1 expressing tumors.
Is Fusion Pharmaceuticals a public or private company?
Fusion Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Fusion Pharmaceuticals founded?
Fusion Pharmaceuticals was founded in 2015. It employs 51 to 100 people.
Where is Fusion Pharmaceuticals based?
Fusion Pharmaceuticals is headquartered in Hamilton, Canada, in the North America region.
How does Fusion Pharmaceuticals make money?
One revenue line is on record: radiopharmaceutical Drug Development and Commercialization.
Who are Fusion Pharmaceuticals's main competitors?
Broad incumbents on record are Novartis, Eli Lilly, Bayer and RayzeBio (Bristol Myers Squibb). Emerging players are Aktis Oncology and Convergent Therapeutics. Direct peers are Telix Pharmaceuticals, Lantheus Holdings, ITM Radiopharma and Point Biopharma.
Does Fusion Pharmaceuticals have an API?
No public API is recorded for Fusion Pharmaceuticals.
What industry is Fusion Pharmaceuticals in?
Fusion Pharmaceuticals's product category is Targeted Alpha Therapeutics / Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.